Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance

Take a look inside the London 2014 Congress


Then register to join us
in Barcelona!


Search Abstracts by author or title
(results will display both Free Papers & Poster)

Customized corneal collagen cross-linking guided by corneal topography in progressive keratoconus

Poster Details

First Author: M.Cassagne FRANCE

Co Author(s):    K. Pierne   P. Fourine   F. Malecaze              

Abstract Details


The aim of the present study was to evaluate the safety and the efficacy of a new procedure of corneal collagen crosslinking (CXL) : a sectoral CXL guided by corneal topography (TG-CXL) in progressive keratoconus.


This prospective, non-randomized study compared the TG-CXL to the conventional CXL (C-CXL). CHU Toulouse, Purpan Hospital, Toulouse, France.


The C-CXL procedure was performed in accordance with the Dresden protocol.
The TG-CXL (KXL II™ System, Avedro Inc, Boston, MA, USA) involved the riboflavin administration (Ricrolin®) on de-epithelialised cornea. This application was followed by a customized pulsed UVA irradiation guided by corneal topography.
Between november 2014 and april 2015, thirty patients with progressive keratoconus were enrolled.
The primary outcome was the stability of keratometric values at 1 year and the secondary outcomes were: visual acuity without correction and best corrected visual acuity, endothelial cell count, anterior segment OCT, aberrometry and complications.


We observed no complications during the procedure, especially concerning the tracking system. Preliminary results showed no difference between TG-CXL and C-CXL.
 No complications were noticed in the two groups concerning the healing process nor the modulation of UVA irradiation.


The safety during the TG-CXL procedure and after a short follow up is good. However, a largest cohort and a longer follow-up is needed to know the results about the efficacy. We will present the results at 3 and 6 months during the meeting.

Financial Disclosure:


Back to Poster listing